The long-acting HIV treatment 'vocabria+rekambys' gets attention whether it will be included in the National Health Insurance reimbursement list, two years after receiving approval in South Korea.

According to industry sources, GSK Korea and Janssen Korea have recently entered drug price negotiations for their new HIV drugs, vocabria (cabotegravir) and rekambys (rilpivirine), respectively. GSK will be responsible for conducting negotiations.

The combination therapy 'vocabria+rekambys' passed the Drug Reimbursement Evaluation Committee (DREC) review of the Health Insurance Review and Assessment Service (HIRA) in December last year.

These two drugs were approved by the Minis